Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study
BackgroundImeglimin, a novel oral hypoglycemic agent, is known to influence mitochondrial function and glucose metabolism. This study evaluates its effects on glycemic control, mitochondrial DNA (mtDNA) copy number, and telomere dynamics in type 2 diabetes mellitus (T2DM).MethodsType 2 diabetes mell...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1585834/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849247208765915136 |
|---|---|
| author | Abhishek Satheesan Janardanan Kumar Kakithakara Vajravelu Leela Ria Murugesan |
| author_facet | Abhishek Satheesan Janardanan Kumar Kakithakara Vajravelu Leela Ria Murugesan |
| author_sort | Abhishek Satheesan |
| collection | DOAJ |
| description | BackgroundImeglimin, a novel oral hypoglycemic agent, is known to influence mitochondrial function and glucose metabolism. This study evaluates its effects on glycemic control, mitochondrial DNA (mtDNA) copy number, and telomere dynamics in type 2 diabetes mellitus (T2DM).MethodsType 2 diabetes mellitus patients were assigned to one of four treatment groups: (1) Imeglimin alone, (2) Imeglimin with metformin, (3) Imeglimin with other oral hypoglycemic agents, and (4) Metformin with other oral hypoglycemic agents. Clinical and metabolic parameters, mtDNA copy number, and relative telomere length were assessed at baseline and six months. Statistical analyses included paired t-tests and mixed models.ResultsThe study included participants with a mean age of 55.6 years (57% male, BMI 28.8 kg/m2). HbA1c significantly decreased in the Imeglimin + Other OHA (p < 0.001), Imeglimin + Metformin (p < 0.001), and Metformin + Other OHA (p < 0.001) groups, with a smaller but significant decrease in the Imeglimin monotherapy group (p = 0.04). mtDNA copy number increased significantly in the Imeglimin-based combination groups (p < 0.05) but not with monotherapy (p = 0.18). No serious adverse events were reported. Relative telomere length was only associated with age and changes in LDL-c levels.ConclusionImeglimin-based combination therapy effectively improves glycemic control and mitochondrial function, while monotherapy offers limited benefits. Combination therapy may be preferable for optimizing metabolic outcomes in T2DM. No significant change in telomere length was observed during the short period of time. |
| format | Article |
| id | doaj-art-9ac20919edb74773ac7f0e22da644a3f |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-9ac20919edb74773ac7f0e22da644a3f2025-08-20T03:58:18ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-08-011610.3389/fendo.2025.15858341585834Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort studyAbhishek Satheesan0Janardanan Kumar1Kakithakara Vajravelu Leela2Ria Murugesan3Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology (SRMIST), Kattankulathur, Chengalpattu, Tamil Nadu, IndiaDepartment of General Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology (SRMIST), Kattankulathur, Chengalpattu, Tamil Nadu, IndiaDepartment of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology (SRMIST), Kattankulathur, Chengalpattu, Tamil Nadu, IndiaDepartment of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology (SRMIST), Kattankulathur, Chengalpattu, Tamil Nadu, IndiaBackgroundImeglimin, a novel oral hypoglycemic agent, is known to influence mitochondrial function and glucose metabolism. This study evaluates its effects on glycemic control, mitochondrial DNA (mtDNA) copy number, and telomere dynamics in type 2 diabetes mellitus (T2DM).MethodsType 2 diabetes mellitus patients were assigned to one of four treatment groups: (1) Imeglimin alone, (2) Imeglimin with metformin, (3) Imeglimin with other oral hypoglycemic agents, and (4) Metformin with other oral hypoglycemic agents. Clinical and metabolic parameters, mtDNA copy number, and relative telomere length were assessed at baseline and six months. Statistical analyses included paired t-tests and mixed models.ResultsThe study included participants with a mean age of 55.6 years (57% male, BMI 28.8 kg/m2). HbA1c significantly decreased in the Imeglimin + Other OHA (p < 0.001), Imeglimin + Metformin (p < 0.001), and Metformin + Other OHA (p < 0.001) groups, with a smaller but significant decrease in the Imeglimin monotherapy group (p = 0.04). mtDNA copy number increased significantly in the Imeglimin-based combination groups (p < 0.05) but not with monotherapy (p = 0.18). No serious adverse events were reported. Relative telomere length was only associated with age and changes in LDL-c levels.ConclusionImeglimin-based combination therapy effectively improves glycemic control and mitochondrial function, while monotherapy offers limited benefits. Combination therapy may be preferable for optimizing metabolic outcomes in T2DM. No significant change in telomere length was observed during the short period of time.https://www.frontiersin.org/articles/10.3389/fendo.2025.1585834/fullImegliminmitochondrial DNAtelomere lengthtype 2 diabetesglycemic control |
| spellingShingle | Abhishek Satheesan Janardanan Kumar Kakithakara Vajravelu Leela Ria Murugesan Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study Frontiers in Endocrinology Imeglimin mitochondrial DNA telomere length type 2 diabetes glycemic control |
| title | Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study |
| title_full | Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study |
| title_fullStr | Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study |
| title_full_unstemmed | Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study |
| title_short | Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study |
| title_sort | effect of imeglimin on mitochondrial function in patients with type 2 diabetes mellitus a prospective cohort study |
| topic | Imeglimin mitochondrial DNA telomere length type 2 diabetes glycemic control |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1585834/full |
| work_keys_str_mv | AT abhisheksatheesan effectofimegliminonmitochondrialfunctioninpatientswithtype2diabetesmellitusaprospectivecohortstudy AT janardanankumar effectofimegliminonmitochondrialfunctioninpatientswithtype2diabetesmellitusaprospectivecohortstudy AT kakithakaravajraveluleela effectofimegliminonmitochondrialfunctioninpatientswithtype2diabetesmellitusaprospectivecohortstudy AT riamurugesan effectofimegliminonmitochondrialfunctioninpatientswithtype2diabetesmellitusaprospectivecohortstudy |